NCT03081156View on ClinicalTrials.gov

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

January 1, 2019

Study Completion Date

January 31, 2019

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler

Exercise Tolerance

Trial Locations (1)

90509

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

All Listed Sponsors
lead

William Stringer, md

OTHER

NCT03081156 - The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD | Biotech Hunter | Biotech Hunter